|Bid||51.38 x 1200|
|Ask||51.49 x 1000|
|Day's range||49.75 - 51.53|
|52-week range||11.65 - 75.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.67|
SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the second quarter ended June 30, 2020 on Tuesday, August 11, 2020. The update will be provided via a press release after market close, and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. CONTACT: Contact: Investors Neera Ravindran, M.D. VP, Head of Investor Relations & Strategic Communications firstname.lastname@example.org +1-415-506-5256 Media Julie Normart W2O Group email@example.com +1-559-974-3245
SAN FRANCISCO, July 07, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.
Vir Biotechnology, Inc. (VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 6,200,000 shares of its common stock. In addition, Vir expects to grant the underwriters a 30-day option to purchase up to 930,000 additional shares of its common stock offered at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined.